<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Iran. J. Public Health</journal-id><journal-id journal-id-type="publisher-id">IJPH</journal-id><journal-id journal-id-type="pmc">IJPH</journal-id><journal-title-group><journal-title>Iranian Journal of Public Health</journal-title></journal-title-group><issn pub-type="ppub">2251-6085</issn><issn pub-type="epub">2251-6093</issn><publisher><publisher-name>Tehran University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28540268</article-id><article-id pub-id-type="pmc">5439041</article-id><article-id pub-id-type="publisher-id">ijph-46-517</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of High and Low Doses of Folic Acid on the Soluble Receptor Activator of Nuclear Factor-kappa B Ligand/Osteoprotegerin Ratio during Pregnancy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>FATHI MAROUFI</surname><given-names>Nazila</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>GHORBANIHAGHJO</surname><given-names>Amir</given-names></name><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>SAYYAH MELLI</surname><given-names>Manizheh</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>VAEZI</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>HEKMATI AZAR MEHRABANI</surname><given-names>Zohreh</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>BANNAZADEH AMIRKHIZ</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>RASHTCHIZADEH</surname><given-names>Nadereh</given-names></name><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref><xref ref-type="corresp" rid="C1"><sup>*</sup></xref></contrib><aff id="AFF1"><label>1.</label> Dept. of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="AFF2"><label>2.</label> Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="AFF3"><label>3.</label> Dept. of Obstetrics and Gynecology, Alzahra Teaching Hospital, Tabriz University of Medical Sciences, Tabriz, Iran</aff></contrib-group><author-notes><corresp id="C1"><label>*</label><bold>Corresponding Author:</bold> Email: <email>rashtchizadeh@roketmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2017</year></pub-date><volume>46</volume><issue>4</issue><fpage>517</fpage><lpage>524</lpage><history><date date-type="received"><day>25</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright&#x000a9; Iranian Public Health Association &#x00026; Tehran University of Medical Sciences</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Pregnancy Associated Osteoporosis (PAO) can lead to serious difficulties such as fragility fractures, elongated back pain and height loss in affected women. Soluble Receptor Activator of Nuclear Factor-Kappa B ligand (sRANKL) to Osteoprotegerin (OPG) ratio is chosen as a bone metabolism equation in many bone diseases characterized by bone resorption, such as post-menopausal osteoporosis and would be modified with folic acid supplementation. This study was done to compare the effects of high dose (5mg/day) and low dose (0.5 mg/day) folic acid in the RANKL/OPG ratio and Tumor Necrosis Factor&#x003b1; (TNF&#x003b1;) concentration during pregnancy.</p></sec><sec><title>Methods:</title><p>Forty-five pregnant women who visited the AL-Zahra Hospital, Tabriz Iran, from September 2013 to November 2014 were assigned into two groups in this randomized, double-blind, clinical trial, included women who took 5 mg/day (group1) and who took 0.5 mg/day (Group 2) folic acid supplementation before pregnancy until 36<sup>th</sup> pregnancy. The biochemical variables in serum of pregnant women were measured before and at the end of the study. The study was registered in the Iranian Registry of Clinical Trials (IRCT) as ID, IRCT2013122315903N1.</p></sec><sec><title>Results:</title><p>OPG levels were significantly higher compared with the baseline value (<italic>P</italic>=0.008), although sRANKL (<italic>P</italic>&#x0003c;0.001), TNF&#x003b1; (<italic>P</italic>=0.005) and sRANKL/OPG ratio (<italic>P</italic>&#x0003c;0.001) reduced significantly with high dose of folic acid supplementation. A significant positive correlation was observed between the decreased RANKL and TNF&#x003b1; levels (r=0.451, <italic>P</italic>=0.031) at the end of study in high dose group.</p></sec><sec><title>Conclusion:</title><p>High dose of folic acid supplementation could decrease bone resorptive biomarkers and may prevent PAO in pregnant women by increasing OPG and decreasing sRANKL and TNF&#x003b1;.</p></sec></abstract><kwd-group><kwd>Folic acid</kwd><kwd>Osteoprotegerin</kwd><kwd>Tumor necrosis factor&#x003b1;</kwd><kwd>Pregnancy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>One of the important issues for all women is bone health, particularly during pregnancy (<xref rid="B1" ref-type="bibr">1</xref>). Pregnancy is associated with the main changes in calcium metabolism because the developing baby needs plenty of calcium in developing its skeleton, which contains approximately 20&#x02013;30 gr of calcium and mainly deposited in the latest trimester (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Adaptive mechanisms involved in protecting a calcium source from pregnant female to the fetus include 1) increased maternal skeleton resorption of calcium and 2) improved intestinal absorption of calcium (<xref rid="B3" ref-type="bibr">3</xref>). Enhanced maternal serum free and total 1, 25 hydroxyvitamin D sounds to be responsible for the better intestinal calcium absorption through pregnancy (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). However, increased dietary intake and intestinal absorption are not adequate to provide the calcium required by the fetus (<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>). Therefore, the maternal skeleton still appears to be the potential source of calcium for the fetus (<xref rid="B9" ref-type="bibr">9</xref>). Bone turnover in pregnant female increases and Bone Mineral Density (BMD) decreases during gestational period (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>).</p><p>The OPG (Osteoprotegerin)/RANKL (Receptor Activator of Nuclear Factor-Kappa B Ligand)/RANK (Receptor Activator of Nuclear Factor-Kappa B) system was discovered recently and seems to play a fundamental role in bone homeostasis (<xref rid="B12" ref-type="bibr">12</xref>). RANKL is a cytokine, which belongs to TNF (Tumor Necrosis Factor) superfamily that regulates the formation and activation of osteoclasts and bone resorption (<xref rid="B13" ref-type="bibr">13</xref>). OPG, another cytokine, is capable of protecting bone mass by inhibiting osteoclast differentiation and activation (<xref rid="B14" ref-type="bibr">14</xref>). The OPG/RANKL ratio is considered better expose of bone remodeling environment signs. A high ratio of OPG/RANKL indicates bone formation, but a lower favors bone resorption (<xref rid="B15" ref-type="bibr">15</xref>). Changes in the OPG/RANKL ratio have been concerned in the pathogenesis of bone diseases characterized by bone resorption, such as post-menopausal osteoporosis (<xref rid="B16" ref-type="bibr">16</xref>), and glucocorticoid-induced osteoporosis (<xref rid="B17" ref-type="bibr">17</xref>). Maternal plasma OPG concentrations increased in the third trimester of pregnancy, a time when the demand for calcium for fetal bone mineralization is at its maximum level and OPG may protect the maternal skeleton from extreme catabolism (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>).</p><p>The effect of folic acid on bone turnover and bone metabolism has been evaluated in previous studies (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). Furthermore, there is evidence that folic acid supplementation has beneficial effects on bone status (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). Tumor Necrosis Factor &#x003b1; (TNF&#x003b1;) is among the most potent of the osteoclastogenic cytokines that stimulate bone resorption both in vitro and in vivo by increasing the proliferation and differentiation of osteoclast precursors (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>Thus far, no studies have investigated the effects of TNF&#x003b1; in pregnancy. The maximum rate of bone turnover occurs in the last trimester of the pregnancy, and folic acid supplementation during pregnancy could result in lower bone resorption rates, the present study was carried out to compare the effects of high dose (5mg/day) and low dose (0.5mg/day) folic acid in the RANKL/OPG ratio and TNF&#x003b1; concentration during the pregnancy.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec sec-type="subjects"><title>Subjects</title><p>In this randomized, double-blind study, ninety nulliparous women visited the Al-Zahra Hospital, Tabriz, Iran and one auxiliary clinic, Specialized and Sub-specialized Sheykholrais Clinic of Tabriz University, Tabriz, Iran for prenatal tests and planning to be pregnant, were enrolled in this follow-up study from September 2013 to November 2014.</p><p>This study protocol was approved by the Ethical Committee of Tabriz University of Medical Sciences (Ethics code: 93/2&#x02013;4/8) and registered in the Iranian Registry of Clinical Trials (IRCT) and given the ID, IRCT2013122315903N1. Written informed consent was obtained from all participants.</p><p>The selection criteria included age between 20&#x02013;31 yr old, singleton pregnancy, have no history of any disease or medication identified to affect bone metabolism, such as chronic hypertension, diabetes mellitus, chronic renal disease, cigarette smoking or alcohol consumption, early miscarriage and assisted conception. Sixty women consequently became pregnant.</p></sec><sec><title>Blinding</title><p>The patients, all persons involved in pregnant women care or treatments, the data collectors, were blind to the treatment distribution. Only the data supervisor of the trial not involved in the treatment or pregnant women care has admission to the treatment distributions.</p></sec><sec sec-type="methods"><title>Sample collection and analysis</title><p>Baseline venous blood samples were collected after overnight fasting at 3-month intervals before conception. After collecting baseline samples, participants received different doses of folic acid (5 mg/d vs. 0.5 mg/d) until 36 wk of pregnancy. The participants were contacted every week and were asked during each visit to declare whether they took folic acid supplementation or not. Second sampling was done in the 36 wk of pregnancy. The participants that had an abortion, multiple pregnancies, usage of calcium and ferrous sulfate during pregnancy and did not complete the follow-up were excluded from the study. Serums were collected after centrifugation (at 3000 RPM) of the samples for 20 min, and then stored at &#x02212;70 &#x000b0;C until analysis. We used the date of the mother&#x02019;s last menstrual period (LMP) for calculating Gestation age. Serum OPG and sRANKL concentrations were measured by commercially Enzyme-Linked Immunosorbent Assay (ELISA) kits (Bioassay Technology Laboratory, China, with intra- and inter- assay CV of &#x0003c;10% and &#x0003c;12%, respectively). TNF&#x003b1; was analyzed in serum by ELISA using Immunodiagnostic kit (DIAsource Immuno Assay S.A, Belgium, with intra- and inter- assay CV of 6.6% and 4.5%, respectively).</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>All of the statistical analyses were performed using SPSS ver. 18 software (SPSS Ins, Chicago, IL). The normality of the distribution of data was tested via the Kolmogorov-Smirnov test. Median (minimum-maximum values), or mean &#x000b1; SD and their percent when appropriate were used to express the results. For unpaired data, the Mann&#x02013; Whitney U-test and Independent sample t-test were used, and the Wilcoxon test and a paired Student <italic>t</italic>-test were used for paired data. Evaluation of the correlation was done with Spearman&#x02019;s test. In all investigated cases <italic>P</italic>-value&#x02264; 0.05, was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Forty-five pregnant women completed follow-up including group 1: twenty-three were treated with 5 mg of folic acid per day and group 2: twenty-two treated with 0.5 mg folic acid per day. Fifteen patients did not complete the study procedure: eight cases had an abortion, two cases had multiple pregnancies and five cases quit taking their supplements. The demographic data and baseline characteristics of two groups are presented in <xref ref-type="table" rid="T1">Table 1</xref>. No significant differences were observed between two groups at the beginning of the study. The maternal serum levels of OPG, sRANKL and TNF&#x003b1; at the baseline and at the 36<sup>th</sup> week of pregnancy in both groups have been shown in <xref ref-type="table" rid="T2">Table 2</xref>. Maternal serum evaluation demonstrated that the levels of OPG in both groups were increased, but only in group 1, there was a statistically significant difference at the 36<sup>th</sup> week of pregnancy compared to baseline (<italic>P</italic>=0.008).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1:</label><caption><p>Demographic data and Clinical characteristics in in each group (Group1: treat with 5 mg and Group2 with 0. 5 mg folic acid)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><bold>Variable</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>Group1(mean&#x000b1;SD)</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>Group2(mean&#x000b1;SD)</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>P</italic> value</bold><sup><bold><xref ref-type="table-fn" rid="TFN2">2</xref></bold></sup></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Maternal age (yr)</td><td align="center" valign="top" rowspan="1" colspan="1">25.34&#x000b1;3.31</td><td align="center" valign="top" rowspan="1" colspan="1">27.04&#x000b1;3.69</td><td align="center" valign="top" rowspan="1" colspan="1">0.077</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pre pregnancy Weight (Kg)</td><td align="center" valign="top" rowspan="1" colspan="1">68.26&#x000b1;7.75</td><td align="center" valign="top" rowspan="1" colspan="1">63.77&#x000b1;5.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.060</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height (cm)</td><td align="center" valign="top" rowspan="1" colspan="1">164.39&#x000b1;3.22</td><td align="center" valign="top" rowspan="1" colspan="1">162.50&#x000b1;3.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.071</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pre pregnancy BMI<xref ref-type="table-fn" rid="TFN1"><sup>1</sup></xref> (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">25.19&#x000b1;2.09</td><td align="center" valign="top" rowspan="1" colspan="1">24.14&#x000b1;1.73</td><td align="center" valign="top" rowspan="1" colspan="1">0.125</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interval (days)</td><td align="center" valign="top" rowspan="1" colspan="1">49.91&#x000b1;20.29</td><td align="center" valign="top" rowspan="1" colspan="1">50.54&#x000b1;19.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.910</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ca(mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">9.01&#x000b1;0.20</td><td align="center" valign="top" rowspan="1" colspan="1">8.95&#x000b1;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.074</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P(mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">3.89&#x000b1;0.15</td><td align="center" valign="top" rowspan="1" colspan="1">3.90&#x000b1;.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.981</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALP (IU/L)</td><td align="center" valign="top" rowspan="1" colspan="1">119.17&#x000b1;36.69</td><td align="center" valign="top" rowspan="1" colspan="1">112.42&#x000b1;34.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.364</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Under diploma</td><td align="center" valign="top" rowspan="1" colspan="1">13(56%)</td><td align="center" valign="top" rowspan="1" colspan="1">11(50%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.317</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High education</td><td align="center" valign="top" rowspan="1" colspan="1">10(43%)</td><td align="center" valign="top" rowspan="1" colspan="1">11(50%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>1</label><p>BMI; Body Mass Index /</p></fn><fn id="TFN2"><label>2</label><p>Values were obtained by Mann&#x02013;Whitney U-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2:</label><caption><p>Laboratory findings of the participants at baseline and at the end of the study after treatment with high dose and low dose of folic acid (Group1: treat with 5 mg and Group2 with 0.5 mg folic acid)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"><bold>Variable</bold></th><th align="left" valign="top" rowspan="1" colspan="1"><bold>Group1(n=23)</bold></th><th align="left" valign="top" rowspan="1" colspan="1"><bold>Group2(n=22)</bold></th><th align="left" valign="top" rowspan="1" colspan="1"><bold><italic>P</italic> value <xref ref-type="table-fn" rid="TFN7"><sup>5</sup></xref></bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Serum OPG<xref ref-type="table-fn" rid="TFN3"><sup>1</sup></xref>(pg/ml)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="center" valign="top" rowspan="1" colspan="1">340(120&#x02013;1200)</td><td align="center" valign="top" rowspan="1" colspan="1">375(160&#x02013;1310)</td><td align="center" valign="top" rowspan="1" colspan="1">0.488</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">36<sup>th</sup>week</td><td align="center" valign="top" rowspan="1" colspan="1">710(120&#x02013;1500)</td><td align="center" valign="top" rowspan="1" colspan="1">470(130&#x02013;1400)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<italic>P</italic>=0.008)<xref ref-type="table-fn" rid="TFN6"><sup>4</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">(<italic>P</italic>=0.592)<xref ref-type="table-fn" rid="TFN6"><sup>4</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Serum sRANKL<xref ref-type="table-fn" rid="TFN4"><sup>2</sup></xref> (pg/ml)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="center" valign="top" rowspan="1" colspan="1">91.6(33.40&#x02013;198.60)</td><td align="center" valign="top" rowspan="1" colspan="1">86.10(39.70&#x02013;198.60)</td><td align="center" valign="top" rowspan="1" colspan="1">0.302</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">36<sup>th</sup>week</td><td align="center" valign="top" rowspan="1" colspan="1">40(20.10&#x02013;100.20)</td><td align="center" valign="top" rowspan="1" colspan="1">76.50(43.70&#x02013;188.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<italic>P</italic>&#x0003c;0.001)<xref ref-type="table-fn" rid="TFN6"><sup>4</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">(<italic>P</italic>=0.426)<xref ref-type="table-fn" rid="TFN6"><sup>4</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Serum TNF&#x003b1;<xref ref-type="table-fn" rid="TFN5"><sup>3</sup></xref> (pg/ml)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="center" valign="top" rowspan="1" colspan="1">5.30(4.10&#x02013;10.20)</td><td align="center" valign="top" rowspan="1" colspan="1">5.85(4.20&#x02013;8.90)</td><td align="center" valign="top" rowspan="1" colspan="1">0.251</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">36<sup>th</sup>week</td><td align="center" valign="top" rowspan="1" colspan="1">4.80(2.50.&#x02013;9.00)</td><td align="center" valign="top" rowspan="1" colspan="1">6.5(5.00&#x02013;8.80)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<italic>P</italic>=0.005)<xref ref-type="table-fn" rid="TFN6"><sup>4</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">(<italic>P</italic>=0.135)<xref ref-type="table-fn" rid="TFN6"><sup>4</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Serum sRANKL/OPG</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="center" valign="top" rowspan="1" colspan="1">0.27 (0.28&#x02013;0.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.23(0.25&#x02013;0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.555</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">36<sup>th</sup>week</td><td align="center" valign="top" rowspan="1" colspan="1">0.06(0.17&#x02013;0.05)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16(0.34&#x02013;0.14)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<italic>P</italic>&#x0003c;0.001)<xref ref-type="table-fn" rid="TFN6"><sup>4</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">(<italic>P</italic>=0.211)<xref ref-type="table-fn" rid="TFN6"><sup>4</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>1</label><p>OPG, Osteoprotegerin;</p></fn><fn id="TFN4"><label>2</label><p>sRANKL, soluble Receptor Activator of Nuclear Factor-kappa B ligand;</p></fn><fn id="TFN5"><label>3</label><p>TNF&#x003b1;, Tumor Necrosis Factor&#x003b1;; Data are expressed as median (minimum&#x02013;maximum).</p></fn><fn id="TFN6"><label>4</label><p>Differences between before treatment and after treatment with high dose or low dose. (Values were obtained by a Wilcoxon test.) /</p></fn><fn id="TFN7"><label>5</label><p>Baseline high dose group vs. low dose group. (Values were obtained by Mann&#x02013;Whitney U-test)</p></fn></table-wrap-foot></table-wrap><p>The concentration of sRANKL (<italic>P</italic>&#x0003c;0.001) and TNF&#x003b1; (<italic>P</italic>=0.005) significantly decreased in the 36<sup>th</sup> week of pregnancy compared to baseline in group 1. As shown in <xref ref-type="table" rid="T2">Table 2</xref> sRANKL/OPG ratio was decreased in both groups but it was statistically significant only in group 1.</p><p>Bivariate correlation analyses confirmed a positive relationship between the decreased sRANKL (Delta sRANKL) with TNF&#x003b1; (Delta TNF&#x003b1;) (r=0.451, <italic>P</italic>=0.031, Delta sRANKL= (sRANKL at the end of study of High-dose folic acid treatment) &#x02014; (sRANKL Basal), Delta TNF&#x003b1;= (TNF&#x003b1; at the end of study of High-dose folic acid treatment) &#x02014; (TNF&#x003b1; Basal)). However, increased OPG levels did not demonstrate an inverse correlation with decreased sRANKL and TNF&#x003b1; levels (r=0.299, <italic>P</italic>=0.166 and r=351, <italic>P</italic>=0.100, respectively) (<xref ref-type="table" rid="T3">Table 3</xref>). The mean changes in serum OPG, sRANKL and TNF&#x003b1; at the end of the study are shown in <xref ref-type="fig" rid="F1">Fig. 1</xref>.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3:</label><caption><p>Correlation statistics in high dose group (5 mg folic acid)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="2" colspan="1"/><th colspan="2" align="center" valign="middle" rowspan="1"><bold>Delta.OPG(pg/ml)</bold></th><th colspan="2" align="center" valign="middle" rowspan="1"><bold>Delta.RANKL(pg/ml)</bold></th><th colspan="2" align="center" valign="middle" rowspan="1"><bold>Delta.TNF&#x003b1;(pg/ml)</bold></th><th colspan="2" align="center" valign="middle" rowspan="1"><bold>Delta.RANKL/OPG</bold></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1"><bold>r</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>P</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>r</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>P</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>r</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>P</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>r</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>P</bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Delta.OPG<xref ref-type="table-fn" rid="TFN9"><sup>1</sup></xref>(pg/ml)</td><td colspan="2" align="center" valign="top" rowspan="1">_</td><td align="center" valign="top" rowspan="1" colspan="1">0.299</td><td align="center" valign="top" rowspan="1" colspan="1">0.166</td><td align="center" valign="top" rowspan="1" colspan="1">0.351</td><td align="center" valign="top" rowspan="1" colspan="1">0.100</td><td align="center" valign="top" rowspan="1" colspan="1">0.497</td><td align="center" valign="top" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Delta.sRANKL<xref ref-type="table-fn" rid="TFN10"><sup>2</sup></xref>(pg/ml)</td><td align="center" valign="top" rowspan="1" colspan="1">0.299</td><td align="center" valign="top" rowspan="1" colspan="1">0.166</td><td colspan="2" align="center" valign="top" rowspan="1">_</td><td align="center" valign="top" rowspan="1" colspan="1">0.451</td><td align="center" valign="top" rowspan="1" colspan="1">0.031<xref ref-type="table-fn" rid="TFN8">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">0.297</td><td align="center" valign="top" rowspan="1" colspan="1">0.218</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Delta.TNF&#x003b1;<xref ref-type="table-fn" rid="TFN11"><sup>3</sup></xref>(pg/ml)</td><td align="center" valign="top" rowspan="1" colspan="1">0.351</td><td align="center" valign="top" rowspan="1" colspan="1">0.100</td><td align="center" valign="top" rowspan="1" colspan="1">0.451</td><td align="center" valign="top" rowspan="1" colspan="1">0.031*</td><td colspan="2" align="center" valign="top" rowspan="1">_</td><td align="center" valign="top" rowspan="1" colspan="1">0.039</td><td align="center" valign="top" rowspan="1" colspan="1">0.859</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Delta.RANKL/OPG<xref ref-type="table-fn" rid="TFN12"><sup>4</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">0.497</td><td align="center" valign="top" rowspan="1" colspan="1">0.016</td><td align="center" valign="top" rowspan="1" colspan="1">0.297</td><td align="center" valign="top" rowspan="1" colspan="1">0.218</td><td align="center" valign="top" rowspan="1" colspan="1">0.039</td><td align="center" valign="top" rowspan="1" colspan="1">0.859</td><td colspan="2" align="center" valign="top" rowspan="1">_</td></tr></tbody></table><table-wrap-foot><fn id="TFN8"><label>*</label><p>Correlation was significant at the 0.05 level.</p></fn><fn id="TFN9"><label>1</label><p>Delta OPG= (OPG at the end of study of High dose folic acid treatment) &#x02014; (OPG Basal)</p></fn><fn id="TFN10"><label>2</label><p>Delta sRANKL= (sRANKL at the end of study of High dose folic acid treatment) &#x02014; (sRANKL Basal)</p></fn><fn id="TFN11"><label>3</label><p>Delta TNF&#x003b1;= (TNF&#x003b1; at the end of study of High dose folic acid treatment) &#x02014; (TNF&#x003b1; Basal)</p></fn><fn id="TFN12"><label>4</label><p>Delta (RANKL/OPG) = (sRANKL/OPG at the end of study of High dose folic acid treatment) &#x02014; (sRANKL/OPG Basal</p></fn></table-wrap-foot></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Fig. 1:</label><caption><p>Effect of folic acid supplementation on Percentile variations in serum osteoprotegerin (OPG), soluble receptor activator of nuclear factor-kappa B ligand (sRANKL) and tumor necrosis factor alpha (TNF&#x003b1;) at the end of study between group 1(5mg/day) vs. group 2 (0.5mg/day)(mean)</p></caption><graphic xlink:href="IJPH-46-517-g001"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Osteoporosis is a universal problem and affects particularly women (<xref rid="B26" ref-type="bibr">26</xref>). PAO seems to be an uncommon problem of pregnancy, but it leads to serious difficulties such as fragility fractures, elongated back pain and height loss in affected women. Definite prevalence of PAO is unknown (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>) but to date, about 120 cases have been defined (<xref rid="B29" ref-type="bibr">29</xref>). In most cases, PAO develops throughout the first pregnancy and recurrence of PAO with future pregnancies is uncommon, but has been reported to occur (<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>). No standard treatment protocol has been established for the handling of PAO, due to the absence of a convinced etiology (<xref rid="B27" ref-type="bibr">27</xref>). PAO causes significant morbidity in the procedure of pain and disability and most patients show various vertebral fractures in the early puerperium and as well as loss of height, which can develop at the end of pregnancy, in the puerperium, or even later (<xref rid="B30" ref-type="bibr">30</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>).</p><p>OPG referred to as &#x0201c;bone protector&#x0201d; is a cytokine that increases the density and volume of bone tissue by reducing a number of active osteoclasts (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B35" ref-type="bibr">35</xref>). RANKL is a member of TNF superfamily and its overexpression of soluble RANKL in transgenic mice results in a skeletal phenotype with many similarities to postmenopausal osteoporosis, including reduced BMD, increased bone resorption, cortical porosity and skeletal fragility (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B34" ref-type="bibr">34</xref>).</p><p>OPG can reserve bone loss in models of sex-steroid insufficiency and glucocorticoid-induced osteoporosis, rheumatoid arthritis, multiple myeloma, and metastatic bone disease (<xref rid="B12" ref-type="bibr">12</xref>). Since OPG directly counters all RANKL mediated activities through RANK, RANKL/OPG ratio has been an important determinant of bone mass and skeleton integrity. In malignant diseases, such as myeloma, osteolytic bone metastases of prostate and breast cancer, enhanced expression of RANKL by tumor cells and tumor-induced increase of the RANKL/OPG ratio in bone microenvironment can be observed (<xref rid="B35" ref-type="bibr">35</xref>). OPG level has progressive increase during pregnancy, with a decrease in serum RANKL (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>). Our results were in accord with these studies; the pregnant women in both groups showed higher levels of OPG in comparison with baseline, which was significant only in high dose group and significant decrease of sRANKL was observed only in high dose group.</p><p>The effect of folic acid was evaluated on bone turnover and bone metabolism (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). The effect of folic acid was evaluated on bone metabolism and turnover during pregnancy (<xref rid="B24" ref-type="bibr">24</xref>). Women who took 1 mg of folic acid daily supplement from the beginning of the pregnancy until the delivery time, had significantly higher plasma levels of OPG concentration and lower sRANKL concentration in comparison with women who took the supplements until the end of the second trimester. For the first time, folic acid supplementation during pregnancy could represent low bone resorption rates by higher OPG and lower sRANKL concentrations (<xref rid="B24" ref-type="bibr">24</xref>). In our study potential effects of high dose and low dose folic acid supplementation in prevention of bone resorption and PAO during pregnancy is investigated. Our results showed that high dose (5 mg/day) of folic acid significantly decreased the concentration of the serum sRANKL and increased serum OPG and for the first time we showed that sRANKL/OPG ratio decreased in high dose group while low dose of folic acid did not have such effects. Inflammatory cytokines such as IL-1, TNF and M-CSF long associated with osteoclastic bone loss, function by stimulating RANKL production by osteoblast precursors and/or development osteoblasts (<xref rid="B36" ref-type="bibr">36</xref>); and/or by decreasing OPG production and/or by up-regulating RANK receptor placement on osteoclast precursors, hence increasing their sensitivity to normal RANKL concentrations (<xref rid="B37" ref-type="bibr">37</xref>).</p><p>For the first time, we evaluated the effects of high dose and low dose of folic acid on serum TNF&#x003b1; levels. These data showed that in high dose group, TNF&#x003b1; decreased significantly and its decrease had a correlation with decreased sRANKL levels. Moreover, TNF&#x003b1; prompts osteoclastogenesis via the RANKL system, as TNF&#x003b1; up-regulates RANKL mRNA expression (<xref rid="B38" ref-type="bibr">38</xref>); and our findings are in agreement with this study. Larger sample size and also measuring new markers of bone resorption, such as serum type 1 collagen C-telopeptide and urine N-telopeptide and bone mineral densitometry will be of great importance to prove the outcomes.</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>The complete mechanism of folic acid special effects on the bone metabolism has not yet been absolutely understood; therefore, a series of researches are necessary to reveal unknown features of this process. High dose of folic acid supplementation could decrease bone resorptive biomarkers and may prevent PAO in pregnant women by increasing OPG level and decreasing sRANKL and TNF&#x003b1; levels.</p><sec><title>Ethical Considerations</title><p>Ethical issues (Including plagiarism, Informed Consent, misconduct, and/or falsification, double publication and/or submission, etc.) have been completely considered by the authors.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>The authors are exceptionally thankful to Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran for financial support and also of all pregnant women who participated in the study. The authors declare that there is no conflict of interest.</p></ack><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cundy</surname><given-names>T</given-names></name><name><surname>Kanis</surname><given-names>JA</given-names></name></person-group> (<year>1981</year>). <article-title>Calcium homoeostasis during pregnancy</article-title>. <source>Br Med J (Clin Res Ed)</source>, <volume>283</volume>:<fpage>562</fpage>&#x02013;<lpage>563</lpage>.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Givens</surname><given-names>MH</given-names></name><name><surname>Macy</surname><given-names>IG</given-names></name></person-group> (<year>1933</year>). <article-title>The chemical composition of the human fetus</article-title>. <source>J Biol Chem</source>, <volume>102</volume>:<fpage>7</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>More</surname><given-names>C</given-names></name><name><surname>Bhattoa</surname><given-names>HP</given-names></name><name><surname>Bettembuk</surname><given-names>P</given-names></name><name><surname>Balogh</surname><given-names>A</given-names></name></person-group> (<year>2003</year>). <article-title>The effects of pregnancy and lactation on hormonal status and biochemical markers of bone turnover</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>, <volume>106</volume>:<fpage>209</fpage>&#x02013;<lpage>213</lpage>.<pub-id pub-id-type="pmid">12551794</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seki</surname><given-names>K</given-names></name><name><surname>Makimura</surname><given-names>N</given-names></name><name><surname>Mitsui</surname><given-names>C</given-names></name><name><surname>Hirata</surname><given-names>J</given-names></name><name><surname>Nagata</surname><given-names>I</given-names></name></person-group> (<year>1991</year>). <article-title>Calcium-regulating hormones and osteocalcin levels during pregnancy: a longitudinal study</article-title>. <source>Am J Obstet Gynecol</source>, <volume>164</volume>:<fpage>1248</fpage>&#x02013;<lpage>1252</lpage>.<pub-id pub-id-type="pmid">2035567</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>NA</given-names></name><name><surname>Hillman</surname><given-names>LS</given-names></name><name><surname>Allen</surname><given-names>SH</given-names></name><name><surname>Krause</surname><given-names>GF</given-names></name><name><surname>Vieira</surname><given-names>NE</given-names></name></person-group> (<year>1995</year>). <article-title>Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study</article-title>. <source>Am J Clin Nutr</source>, <volume>61</volume>:<fpage>514</fpage>&#x02013;<lpage>523</lpage>.<pub-id pub-id-type="pmid">7872214</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowers</surname><given-names>M</given-names></name><name><surname>Scholl</surname><given-names>T</given-names></name><name><surname>Harris</surname><given-names>L</given-names></name><name><surname>Jannausch</surname><given-names>M</given-names></name></person-group> (<year>2000</year>). <article-title>Bone loss in adolescent and adult pregnant women</article-title>. <source>Obstet Gynecol</source>, <volume>96</volume>:<fpage>189</fpage>&#x02013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">10908761</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>D</given-names></name><name><surname>Kaur</surname><given-names>M</given-names></name><name><surname>San</surname><given-names>P</given-names></name><name><surname>Lawson</surname><given-names>N</given-names></name><name><surname>Baker</surname><given-names>P</given-names></name><name><surname>Hosking</surname><given-names>D</given-names></name></person-group> (<year>2004</year>). <article-title>Recovery of pregnancy mediated bone loss during lactation</article-title>. <source>Bone</source>, <volume>34</volume>:<fpage>570</fpage>&#x02013;<lpage>578</lpage>.<pub-id pub-id-type="pmid">15003805</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Promislow</surname><given-names>JH</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name><name><surname>Schramm</surname><given-names>M</given-names></name><name><surname>Watt-Morse</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>JJ</given-names></name></person-group> (<year>2004</year>). <article-title>Bed rest and other determinants of bone loss during pregnancy</article-title>. <source>Am J Obstet Gynecol</source>, <volume>191</volume>:<fpage>1077</fpage>&#x02013;<lpage>1083</lpage>.<pub-id pub-id-type="pmid">15507924</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>CS</given-names></name><name><surname>Kronenberg</surname><given-names>HM</given-names></name></person-group> (<year>1997</year>). <article-title>Maternal-Fetal Calcium and Bone Metabolism During Pregnancy, Puerperium, and Lactation 1</article-title>. <source>Endocr Rev</source>, <volume>18</volume>:<fpage>832</fpage>&#x02013;<lpage>872</lpage>.<pub-id pub-id-type="pmid">9408745</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Affinito</surname><given-names>P</given-names></name><name><surname>Tommaselli</surname><given-names>GA</given-names></name><name><surname>di Carlo</surname><given-names>C</given-names></name><name><surname>Guida</surname><given-names>F</given-names></name><name><surname>Nappi</surname><given-names>C</given-names></name></person-group> (<year>1996</year>). <article-title>Changes in bone mineral density and calcium metabolism in breastfeeding women: a one year follow-up study</article-title>. <source>J Clin Endocrinol Metab</source>, <volume>81</volume>:<fpage>2314</fpage>&#x02013;<lpage>2318</lpage>.<pub-id pub-id-type="pmid">8964870</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>A</given-names></name><name><surname>Topping</surname><given-names>J</given-names></name><name><surname>Durham</surname><given-names>B</given-names></name><name><surname>Farquharson</surname><given-names>R</given-names></name><name><surname>Fraser</surname><given-names>W</given-names></name></person-group> (<year>2000</year>). <article-title>A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy</article-title>. <source>J Bone Miner Res</source>, <volume>15</volume>:<fpage>557</fpage>&#x02013;<lpage>563</lpage>.<pub-id pub-id-type="pmid">10750571</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyce</surname><given-names>BF</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name></person-group> (<year>2008</year>). <article-title>Functions of RANKL\RANK\OPG in bone modeling and remodeling</article-title>. <source>Arch Biochem Biophys</source>, <volume>473</volume>:<fpage>139</fpage>&#x02013;<lpage>146</lpage>.<pub-id pub-id-type="pmid">18395508</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyce</surname><given-names>BF</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name></person-group> (<year>2007</year>). <article-title>Biology of RANK, RANKL, and osteoprotegerin</article-title>. <source>Arthritis Res Ther</source>, <volume>1</volume>:<fpage>S1</fpage>.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J-S</given-names></name><name><surname>Santolaya-Forgas</surname><given-names>J</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Espinoza</surname><given-names>J</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>LF</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Edwin</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>BH</given-names></name><name><surname>Nien</surname><given-names>JK</given-names></name><name><surname>Hassan</surname><given-names>S</given-names></name></person-group> (<year>2005</year>). <article-title>Maternal plasma osteoprotegerin concentration in normal pregnancy</article-title>. <source>Am J Obstet Gynecol</source>, <volume>193</volume>:<fpage>1011</fpage>&#x02013;<lpage>1015</lpage>.<pub-id pub-id-type="pmid">16157103</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>I</given-names></name><name><surname>Branco</surname><given-names>J</given-names></name></person-group> (<year>2011</year>). <article-title>Rank\Rankl\opg: literature review</article-title>. <source>Acta Reumatol Port</source>, <volume>36</volume>:<fpage>209</fpage>&#x02013;<lpage>218</lpage>.<pub-id pub-id-type="pmid">22113597</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eghbali-Fatourechi</surname><given-names>G</given-names></name><name><surname>Khosla</surname><given-names>S</given-names></name><name><surname>Sanyal</surname><given-names>A</given-names></name><name><surname>Boyle</surname><given-names>WJ</given-names></name><name><surname>Lacey</surname><given-names>DL</given-names></name><name><surname>Riggs</surname><given-names>BL</given-names></name></person-group> (<year>2003</year>). <article-title>Role of RANK ligand in mediating increased bone resorption in early postmenopausal women</article-title>. <source>J Clin Invest</source>, <volume>111</volume>:<fpage>1221</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">12697741</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Kusano</surname><given-names>E</given-names></name><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Yano</surname><given-names>K</given-names></name><name><surname>Tsuda</surname><given-names>E</given-names></name><name><surname>Asano</surname><given-names>Y</given-names></name></person-group> (<year>2001</year>). <article-title>Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis</article-title>. <source>Nephrol Dial Transplant</source>, <volume>16</volume>:<fpage>479</fpage>&#x02013;<lpage>482</lpage>.<pub-id pub-id-type="pmid">11239019</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>K</given-names></name><name><surname>Rogers</surname><given-names>A</given-names></name><name><surname>Fraser</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>V</given-names></name><name><surname>Eastell</surname><given-names>R</given-names></name><name><surname>Blumsohn</surname><given-names>A</given-names></name></person-group> (<year>2003</year>). <article-title>Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation</article-title>. <source>J Clin Endocrinol Metab</source>, <volume>88</volume>:<fpage>5361</fpage>&#x02013;<lpage>5365</lpage>.<pub-id pub-id-type="pmid">14602774</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>H</given-names></name><name><surname>Yasui</surname><given-names>T</given-names></name><name><surname>Kiyokawa</surname><given-names>M</given-names></name><name><surname>Kuwahara</surname><given-names>A</given-names></name><name><surname>Ikawa</surname><given-names>H</given-names></name><name><surname>Matsuzaki</surname><given-names>T</given-names></name><name><surname>Maegawa</surname><given-names>M</given-names></name><name><surname>Furumoto</surname><given-names>H</given-names></name><name><surname>Irahara</surname><given-names>M</given-names></name></person-group> (<year>2002</year>). <article-title>Serum osteoprotegerin\osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers</article-title>. <source>J Endocrinol</source>, <volume>174</volume>:<fpage>353</fpage>&#x02013;<lpage>359</lpage>.<pub-id pub-id-type="pmid">12176675</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yano</surname><given-names>K</given-names></name><name><surname>Shibata</surname><given-names>O</given-names></name><name><surname>Mizuno</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>F</given-names></name><name><surname>Higashio</surname><given-names>K</given-names></name><name><surname>Morinaga</surname><given-names>T</given-names></name><name><surname>Tsuda</surname><given-names>E</given-names></name></person-group> (<year>2001</year>). <article-title>Immunological study on circulating murine osteoprotegerin\osteoclastogenesis inhibitory factor (OPG\OCIF): possible role of OPG\OCIF in the prevention of osteoporosis in pregnancy</article-title>. <source>Biochem Biophys Res Commun</source>, <volume>288</volume>:<fpage>217</fpage>&#x02013;<lpage>224</lpage>.<pub-id pub-id-type="pmid">11594776</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xian</surname><given-names>CJ</given-names></name><name><surname>Cool</surname><given-names>JC</given-names></name><name><surname>Scherer</surname><given-names>MA</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Foster</surname><given-names>BK</given-names></name></person-group> (<year>2008</year>). <article-title>Folinic acid attenuates methotrexate chemotherapy - induced damages on bone growth mechanisms and pools of bone marrow stromal cells</article-title>. <source>J Cell Physiol</source>, <volume>214</volume>:<fpage>777</fpage>&#x02013;<lpage>785</lpage>.<pub-id pub-id-type="pmid">17786974</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>MS</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name><name><surname>Selhub</surname><given-names>J</given-names></name></person-group> (<year>2005</year>). <article-title>Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans</article-title>. <source>Bone</source>, <volume>37</volume>:<fpage>234</fpage>&#x02013;<lpage>242</lpage>.<pub-id pub-id-type="pmid">15950558</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Iwamoto</surname><given-names>J</given-names></name><name><surname>Kanoko</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name></person-group> (<year>2005</year>). <article-title>Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial</article-title>. <source>JAMA</source>, <volume>293</volume>:<fpage>1082</fpage>&#x02013;<lpage>1088</lpage>.<pub-id pub-id-type="pmid">15741530</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossein-nezhad</surname><given-names>A</given-names></name><name><surname>Mirzaei</surname><given-names>K</given-names></name><name><surname>Maghbooli</surname><given-names>Z</given-names></name><name><surname>Najmafshar</surname><given-names>A</given-names></name><name><surname>Larijani</surname><given-names>B</given-names></name></person-group> (<year>2011</year>). <article-title>The influence of folic acid supplementation on maternal and fetal bone turnover</article-title>. <source>J Bone Miner Metab</source>, <volume>29</volume>:<fpage>186</fpage>&#x02013;<lpage>192</lpage>.<pub-id pub-id-type="pmid">20602129</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>J</given-names></name><name><surname>Takeshita</surname><given-names>S</given-names></name><name><surname>Barker</surname><given-names>JE</given-names></name><name><surname>Kanagawa</surname><given-names>O</given-names></name><name><surname>Ross</surname><given-names>FP</given-names></name><name><surname>Teitelbaum</surname><given-names>SL</given-names></name></person-group> (<year>2000</year>). <article-title>TNF-&#x003b1; induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand</article-title>. <source>J Clin Invest</source>, <volume>106</volume>:<fpage>1481</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11120755</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sar&#x00131;kaya</surname><given-names>S</given-names></name><name><surname>&#x000d6;zdolap</surname><given-names>&#x0015e;</given-names></name><name><surname>A&#x000e7;&#x00131;kg&#x000f6;z</surname><given-names>G</given-names></name><name><surname>Erdem</surname><given-names>CZ</given-names></name></person-group> (<year>2004</year>). <article-title>Pregnancy-associated osteoporosis with vertebral fractures and scoliosis</article-title>. <source>Joint Bone Spine</source>, <volume>71</volume>:<fpage>84</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">14769530</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>H</given-names></name><name><surname>Petrovsky</surname><given-names>N</given-names></name></person-group> (<year>2002</year>). <article-title>Pregnancy - associated osteoporosis with hypercalcaemia</article-title>. <source>Intern Med J</source>, <volume>32</volume>:<fpage>481</fpage>&#x02013;<lpage>485</lpage>.<pub-id pub-id-type="pmid">12380703</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anai</surname><given-names>T</given-names></name><name><surname>Tomiyasu</surname><given-names>T</given-names></name><name><surname>Arima</surname><given-names>K</given-names></name><name><surname>Miyakawa</surname><given-names>I</given-names></name></person-group> (<year>1999</year>). <article-title>Pregnancy - Associated Osteoporosis with Elevated Levels of Circulating Parathyroid Hormone - Related Protein: A Report of Two Cases</article-title>. <source>J Obstet Gynaecol Res</source>, <volume>25</volume>:<fpage>63</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">10067016</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choe</surname><given-names>EY</given-names></name><name><surname>Song</surname><given-names>JE</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Seok</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Lim</surname><given-names>S-K</given-names></name><name><surname>Rhee</surname><given-names>Y</given-names></name></person-group> (<year>2012</year>). <article-title>Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures</article-title>. <source>J Bone Miner Metab</source>, <volume>30</volume>:<fpage>596</fpage>&#x02013;<lpage>601</lpage>.<pub-id pub-id-type="pmid">22105654</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalkwarf</surname><given-names>HJ</given-names></name><name><surname>Specker</surname><given-names>BL</given-names></name></person-group> (<year>2002</year>). <article-title>Bone mineral changes during pregnancy and lactation</article-title>. <source>Endocrine</source>, <volume>17</volume>:<fpage>49</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">12014704</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaga</surname><given-names>A</given-names></name><name><surname>Taga</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Shirai</surname><given-names>T</given-names></name></person-group> (<year>2000</year>). <article-title>A case of postpregnancy osteoporosis</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>, <volume>88</volume>:<fpage>107</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">10659928</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Tanizawa</surname><given-names>T</given-names></name><name><surname>Kawashima</surname><given-names>T</given-names></name><name><surname>Endo</surname><given-names>N</given-names></name></person-group> (<year>1994</year>). <article-title>Bone mineral density and bone histomorphometric assessments of postpregnancy osteoporosis: a report of five patients</article-title>. <source>Calcif Tissue Int</source>, <volume>54</volume>:<fpage>20</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">8118748</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Gregorio</surname><given-names>S</given-names></name><name><surname>Danilowicz</surname><given-names>K</given-names></name><name><surname>Rubin</surname><given-names>Z</given-names></name><name><surname>Mautalen</surname><given-names>C</given-names></name></person-group> (<year>2000</year>). <article-title>Osteoporosis with vertebral fractures associated with pregnancy and lactation</article-title>. <source>Nutrition</source>, <volume>16</volume>:<fpage>1052</fpage>&#x02013;<lpage>1055</lpage>.<pub-id pub-id-type="pmid">11118824</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;sullivan</surname><given-names>S</given-names></name><name><surname>Grey</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Reid</surname><given-names>I</given-names></name></person-group> (<year>2006</year>). <article-title>Bisphosphonates in pregnancy and lactation-associated osteoporosis</article-title>. <source>Osteoporos Int</source>, <volume>17</volume>:<fpage>1008</fpage>&#x02013;<lpage>1012</lpage>.<pub-id pub-id-type="pmid">16758139</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klejna</surname><given-names>K</given-names></name><name><surname>Naumnik</surname><given-names>B</given-names></name><name><surname>Gasowska</surname><given-names>K</given-names></name><name><surname>My&#x0015b;liwiec</surname><given-names>M</given-names></name></person-group> (<year>2009</year>). <article-title>OPG\RANK\RANKL signaling system and its significance in nephrology</article-title>. <source>Folia Histochem Cytobiol</source>, <volume>47</volume>:<fpage>199</fpage>&#x02013;<lpage>206</lpage>.<pub-id pub-id-type="pmid">19995704</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Kitaura</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Ross</surname><given-names>FP</given-names></name><name><surname>Teitelbaum</surname><given-names>SL</given-names></name></person-group> (<year>2005</year>). <article-title>IL-1 mediates TNF-induced osteoclastogenesis</article-title>. <source>J Clin Invest</source>, <volume>115</volume>:<fpage>282</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">15668736</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weitzmann</surname><given-names>MN</given-names></name></person-group> (<year>2013</year>). <article-title>The role of inflammatory cytokines, the RANKL\OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis</article-title>. <source>Scientifica</source>, <volume>2013</volume>:<fpage>125705</fpage>.<pub-id pub-id-type="pmid">24278766</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y-H</given-names></name><name><surname>Heulsmann</surname><given-names>A</given-names></name><name><surname>Tondravi</surname><given-names>MM</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name></person-group> (<year>2001</year>). <article-title>Tumor necrosis factor-&#x003b1; (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways</article-title>. <source>J Biol Chem</source>, <volume>276</volume>:<fpage>563</fpage>&#x02013;<lpage>568</lpage>.<pub-id pub-id-type="pmid">11032840</pub-id></mixed-citation></ref></ref-list></back></article>